durvalumab,tremelimumab
astrazeneca
[]
infinity study of dual io neoadjuvant therapy durva/treme in resectable ge junction tumors in msi-h #cancer (n=15) with impressive rr but gr 5 toxicities (n=3). more data needed!! #ascogi #cancerresearch #clinicaltrials #ascogi23 #cancerresearch 
Co-Director/Co-Leader GI Oncology Research; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee; and Director for Strategic Relations